NCT03448731

Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)

Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.

Conditions

• Skin Toxicity

Interventions

Type	Name	Description
DRUG	Doxycycline 50Mg Tablet	Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1

Timeline

• Start date: 2018-05-10
• Primary completion: 2020-04-06
• Completion: 2020-04-06
• First posted: 2018-02-28
• Last updated: 2020-04-08

Locations

8 sites across 1 country: Spain